Most men who start testosterone cypionate get the symptom relief they wanted and the fertility loss they did not plan for. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, dropping LH and FSH and collapsing intratesticular testosterone concentrations that sperm production requires. For men who may want children, or who simply prefer to keep their own production online, the standard TRT injection is the wrong tool.
Enclomiphene citrate is the trans-isomer of clomiphene, isolated from the zuclomiphene enantiomer that contributed to mixed side effects in older clomiphene studies. It works as a selective estrogen receptor modulator (SERM) in the hypothalamus, blocking estrogen negative feedback and thereby increasing GnRH pulse frequency, LH secretion, FSH secretion, and downstream testicular testosterone synthesis. The result is higher serum testosterone with preserved or improved spermatogenesis in many men, a fundamentally different pharmacologic strategy than injection.
The HPG axis problem TRT creates
The testis needs high local testosterone concentrations (orders of magnitude above serum levels) to support spermatogenesis. When you inject testosterone, the pituitary sees adequate circulating androgen and reduces LH/FSH output. The testes receive less stimulation. Intratesticular testosterone falls. Sperm counts drop, often to azoospermia within months.
This is predictable physiology, not a side effect in the traditional sense. Men on TRT who want fertility need adjunct hCG (LH mimic), enclomiphene, or a switch off exogenous testosterone entirely, each with tradeoffs.
How enclomiphene differs from clomiphene
Clomiphene citrate (Clomid) is a racemic mixture: 38% enclomiphene (trans-isomer) and 62% zuclomiphene (cis-isomer). Both are SERMs, but zuclomiphene has a longer half-life and more estrogenic activity at some tissues, contributing to mood variability, visual disturbances, and inconsistent testosterone response in some patients.
Enclomiphene isolates the more favorable isomer. The FDA has not approved enclomiphene for male hypogonadism as of 2026, but it is widely prescribed off-label and studied in Phase 3 programs for men with low testosterone who wish to preserve fertility. Compounded and branded formulations (Androxal was the historical development name) circulate in telehealth men's health.
Clinical trial evidence
A pivotal Phase 2 study in overweight men with secondary hypogonadism compared enclomiphene 12.5 mg and 25 mg daily to topical testosterone gel and placebo over three months. Enclomiphene raised mean total testosterone into the mid-normal range with sustained LH and FSH elevation, while topical testosterone suppressed gonadotropins as expected. Sexual function and symptom scores improved in the enclomiphene arms.
Longer-term data presented in subsequent analyses showed maintenance of testosterone elevation at 6 months with continued gonadotropin stimulation. Sperm parameters were preserved or improved in men who entered the study with intact spermatogenesis, which is the central differentiator from TRT.
A 2025 systematic review in World Journal of Men's Health pooled enclomiphene studies and reported consistent testosterone increases, favorable gonadotropin profiles, and sperm preservation advantages versus exogenous testosterone, while noting that head-to-head quality-of-life comparisons with TRT remain limited and long-term cardiovascular outcomes require more data.
Who is a candidate?
Enclomiphene is most appropriate for men with:
- Secondary hypogonadism (low testosterone with low or inappropriately normal LH, suggesting hypothalamic-pituitary dysfunction rather than primary testicular failure)
- Desire for future fertility or active attempts to conceive
- Preference for oral daily therapy over injections
- Testosterone levels in the mildly low to low-normal range where stimulation may suffice
It is less appropriate for men with primary testicular failure (Klinefelter syndrome, post-chemotherapy, severe testicular atrophy) where the testis cannot respond to LH/FSH signaling regardless of stimulation. It is also a poor fit for men who need rapid, reliable supraphysiologic normalization because response is variable and titration takes weeks.
Dosing and titration
Standard starting doses in trials and telehealth practice are 12.5 mg or 25 mg daily, often compounded as capsules. Some protocols use 12.5 mg daily for two weeks, then increase to 25 mg based on morning total testosterone and symptom response.
Unlike injectable TRT, peak-trough swings are minimal because the mechanism is continuous axis stimulation rather than depot release. Morning testosterone should be rechecked at 6 to 8 weeks after initiation or dose change. Target remains mid-normal physiologic range, not the highest number on the lab report.
Monitoring on enclomiphene
Lab surveillance overlaps with TRT but is not identical:
- Total and free testosterone at baseline, 6 to 8 weeks, then every 3 to 6 months
- LH and FSH, should remain elevated or normalized upward; suppressed gonadotropins suggest misdiagnosis or noncompliance
- Estradiol, increased testosterone aromatizes to estradiol; gynecomastia can occur and may require dose adjustment
- Semen analysis for fertility-focused patients at 3 to 6 months
- Hematocrit, rises less predictably than on TRT but still warrants periodic CBC monitoring
- PSA per standard men's health screening intervals
Side effects
Enclomiphene is generally well tolerated. Reported adverse effects in trials include headache, nausea, visual disturbance (rare, as with all clomiphene-class drugs), and mood changes. Visual symptoms warrant immediate discontinuation and ophthalmology evaluation, per standard SERM precautions.
Gynecomastia reflects aromatization of the additional testosterone produced, not direct estrogenic activity of enclomiphene at breast tissue in most cases. Management may include dose reduction or targeted anti-estrogen therapy under supervision.
Enclomiphene vs. injectable TRT
| Factor | Enclomiphene | Testosterone cypionate |
|---|---|---|
| Mechanism | Stimulates endogenous production | Replaces with exogenous hormone |
| Fertility | Usually preserved or improved | Typically suppresses sperm production |
| Route | Oral daily | Injection 1-2x weekly |
| Response predictability | Variable; requires titration | Highly predictable dose-response |
| Hematocrit risk | Generally lower | Common dose-limiting effect |
| Testicular volume | Maintained | Often atrophies over time |
Enclomiphene plus TRT: not standard
Some clinicians experiment with low-dose enclomiphene alongside TRT to preserve testicular function, but this is not guideline-established and may produce unpredictable estrogen and gonadotropin dynamics. hCG is the more evidence-backed TRT adjunct for intratesticular stimulation. Patients should not combine therapies without explicit prescriber oversight.
Switching from TRT to enclomiphene
Men who started injectable testosterone and later want fertility must stop TRT and often wait months for the axis to recover before enclomiphene or gonadotropin therapy can work. A washout period plus hCG bridge is common in reproductive urology. Starting enclomiphene while still on weekly injections will not restore fertility.
Regulatory and access notes
Enclomiphene remains off-label for hypogonadism in the US market despite substantial clinical development. Compounded 12.5 mg capsules are the typical telehealth delivery format. Patients should understand the regulatory status: studied, commonly prescribed, not FDA-approved for this indication at the time of writing.
CLYR Health offers enclomiphene for men whose licensed providers determine fertility-preserving testosterone stimulation is appropriate. It is an alternative pathway, not a universal substitute for TRT, the right choice depends on hypogonadism type, fertility goals, symptom severity, and how each patient's axis responds to stimulation.